NSAIDs, coxibs, and the intestine

Journal of Cardiovascular Pharmacology

Volumn 47, Issue SUPPL. 1, 2006, Pages

  Hawkey, C J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Anemia; COX 2 inhibitors; Crohn's disease; Intestine; NSAIDs; Ulcerative colitis

Indexed keywords

ANALGESIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ANEMIA; ARTICLE; CROHN DISEASE; DIAPHRAGM DISEASE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG MECHANISM; DRUG USE; ENDOSCOPY; ENTERITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; INTESTINE INJURY; INTESTINE ULCER; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RISK MANAGEMENT; RISK REDUCTION; STOMACH EROSION; ULCERATIVE COLITIS;

ANEMIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; RISK FACTORS;

EID: 33750433244     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200605001-00013     Document Type: Article

References (49)

1. Hawkey CJ. COX-2 chronology. Gut. 2005;54:1509-1514.
2. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2005;21:169-175.
3. Day RO. Intestinal perforation associated with osmotic slow release indomethacin capsules. BMJ. 1983;287:1671-1672.
4. Morris AJ, Madhok R, Sturrock RD, et al. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet. 1991;337:520.
5. Allison MC, Howatson A, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992;327:749-754.
6. Bjarnason I, Hayllar J, MacPherson AJ, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832-1847.
7. Hudson N, Wilkinson MJ, Swannell AJ, et al. Ileo-caecal ulceration associated with the use of diclofenac slow release. Aliment Pharmacol Therap. 1993;7:197-200.
8. Lengeling RW, Mitros FA, Brennan JA, et al. Ulcerative ileitis encountered at ileo-colonoscopy: likely role of nonsteroidal agents. Clin Gas Hepatol. 2003;1:160-169.
9. Whitcomb DC, Martin SP, Trellis DR, et al. 'Diaphragm like' stricture and ulcer of the colon during diclofenac treatment. Arch Int Med. 1992;152:2341-2343.
10. Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ. 1985;290:347-349.
11. Bartle WR, Gupta AK, Lazor J. Nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding. A case-control study. Arch Intern Med. 1986;146:2365-2367.
12. Collins AJ. Upper gastrointestinal findings and faecal blood in patients with rhematic diseases taking NSAIDs. Br J Rheumatol. 1987;26:295-298.
13. Mpofu S, Mpofu CM, Hutchinson D, et al. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis. 2004;63:588-590.
14. Morris CR, Harvey IM, Stebbings WS, et al. Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg. 2003;90:1267-1272.
15. Goh H, Bourne R. Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study. Ann Roy Coll Surg Eng. 2002;84:93-96.
16. Aldoori WH, Giovannucci EL, Rimm EB, et al. Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. Arch Family Med. 1998;7:255-260.
17. Foutch PG. Diverticular bleeding: are nonsteroidal anti-inflammatory drugs risk factors for hemorrhage and can colonoscopy predict outcome for patients? Am J Gastroenterol. 1995;90:1779-1784.
18. Campbell K, Steele RJ. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case-control study. Br J Surg. 1991;78:190-191.
19. Davies NM. Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Sci. 1999;2:5-14.
20. Bjarnasson I, Clark P, et al. Effect of prostaglandin on indemothacin-induced increased intestinal permeability in man. Scand J Gastroenterol. 1989;164:97-102.
21. Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut. 1983;24:187-189.
22. Evans JMM, McMahon AD, Murray FE, et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40:619-622.
23. Felder JB, Korelitz BI, Rajapakse R, et al. Effect of NSAID drugs on inflammatory bowel disease: a case control study. Am J Gastroenterol. 2000;85:1949-1955.
24. Hall RI, Pretty AH, Cobden I, et al. Enteritis and colitis associated with mefenamic acid. BMJ. 1983;287:1182.
25. Isaacs PET, Filpie I. Mefenamic acid enteropathy. J Clin Pathol. 1987;40:1121-1127.
26. Dominitz JA, Koepsell TD, Boyko EJ, et al. Association between analgesic use and inflammatory bowel disease (IBD) flares: a retrospective cohort study. Gastroenterology. 2000;118:A3024.
27. Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a casecontrol study. Gut. 1992;33:683-686.
28. Hawkey CJ, Jones JI, Atherton CT, et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut. 2003;52:1537-1542.
29. Atherton C, Jones J, McKaig B, et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study. Clin Gastroenterol Hepatology. 2004;2:113-120.
30. Graham DY, Opekun AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastro Hepatol. 2005;3:55-59.
31. Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172-1178.
32. Gomez-Rodriguez B, Caunedo-Alvarez A, Romero-Vazque J, et al. NSAIDs ersoive enteropathy assessed by capsule endoscopy. Gastroenterology. 2004;126:A96.
33. Bjarnason I, Hayllar J, Smethurst P, et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut. 1992;33:1204-1208.
34. Reuter BK, Wallace JL. NSAID enteropathy in rats: role of permeability, bacteria and enterohepatic circulation. Gastroenterology. 1997;112:109-117.
35. Bjarnason I, Zanelli G, Prouse P, et al. Treatment of non-steroidal anti-inflammatory drug induced enteropathy. Gut. 1990;31:777-780.
36. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
37. Bombardier C, Laine L, Reicin A, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 2000;343:1520-1528.
38. Schnitzer TJ, Burmester GR, Mysler E, et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665-674.
39. Sigthorsson G, Crane R, Simon T, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut. 2000;47:527-532.
40. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastro Hepatol. 2005;3:133-141.
41. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124:288-292.
42. Upadhyay R, Torley HI, McKinlay AW, et al. Iron deficiency anemia in patients with rheumatic disease receiving non-steroidal anti-inflammatory drugs: the role of upper gastrointestinal lesions. Ann Rheum Dis. 1990;49:359-362.
43. Weinstein W, Smalley W, Ehrsam E, et al. Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) of lumiracoxib vs naproxen and ibuprofen: incidence of anaemia. Gastroenterology. 2005;128:A638.
44. Bjarnason I, Zanelli G, Prouse P, et al., Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet. 1987;2:711-714.
45. Collins AJ, Du Toit JA. Upper gastrointestinal findings and faecal occult blood in patients with rheumatic diseases taking nonsteroidal anti-inflammatory drugs. Br J Rheumatol. 1987;26:295-298.
46. Hunt RH, Bowen B, Mortensen ER, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med. 2000;109:201-206.
47. Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Therap. 2003;17:201-210.
48. Mahadevan U, Loftex EV Jr, Tremaine WJ, et al. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97:910-914.
49. Matuk R, Crawford J, Avreu MT, et al. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:352-356.